Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2021

View Archived Issues

New phase I/II study of bintrafusp alfa with M-9241 and docetaxel in metastatic prostate cancer

Movement strengthens bones, and immunity

Atherosclerosis precedes clonal hematopoiesis

Ascendis initiates phase III trial of TransCon PTH for hypoparathyroidism

PIPE-307 enters phase I development as potential treatment of multiple sclerosis

Cancer-associated fibroblasts influence GIST progression and metastasis through PDGFC secretion

GcgR antagonist enhances functional beta-cell mass and glycemic control in type 1 diabetes

Topline data from BRAVE-AA2 phase III study of baricitinib in severe alopecia areata

MediciNova discontinues development of vaccine for COVID-19

FDA accepts IND application for EP-7041 for thrombosis prevention in patients with COVID-19

Guangdong Xiangxue Life Sciences patents TCRs targeting AFP-derived short peptide

New IRAK-4 inhibitors identified at Bristol Myers Squibb

Alkermes presents new mu-opioid receptor agonists

Ankh Life Sciences describes new anticancer compounds

Xentria submits IND application to the FDA for XTMAB-16 as treatment of sarcoidosis

Arbutus Biopharma identifies HBsAg secretion inhibitors

Wellmarker Bio receives phase I study approval for WM-S1-030 in Australia

Galapagos reports interim data from safety studies of filgotinib

Positive topline data from phase II program of AZR-MD-001 in Meibomian gland dysfunction

PHA-022121 shows promise for treating hereditary angioedema

Benralizumab achieves OCS elimination or reduction in OCS-dependent asthmatics

MiR-939-5p, tumor suppressor and potential therapeutic target in TNBC

FDA clears IND for pilot study of NVD-003 for congenital pseudarthrosis of the tibia

FDA clears initiation of phase I study of DT-2216 for solid tumors

COVID-eVax vaccine enters phase I/II study

CFI-402257 plus paclitaxel shows manageable safety in HER2-negative breast cancer patients

Nuformix reports preclinical data on NXP-002 in combination therapy for IPF

"Confounders" could be bountiful harvest rather than nuisance in epigenomics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...